NeuroPace Inc. (NPCE)
11.84
-0.54 (-4.36%)
At close: Mar 28, 2025, 3:59 PM
11.85
0.08%
After-hours: Mar 28, 2025, 04:05 PM EDT
Company Description
NeuroPace, Inc. operates as a medical device company in the United States.
It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source.
The company's RNS system also records continuous brain activity data; and enables clinicians to monitor patients in person and remotely.
It sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures.
The company was incorporated in 1997 and is headquartered in Mountain View, California.
NeuroPace Inc.

Country | United States |
IPO Date | Apr 22, 2021 |
Industry | Medical - Devices |
Sector | Healthcare |
Employees | 184 |
CEO | Joel D. Becker |
Contact Details
Address: 455 North Bernardo Avenue Mountain View, California United States | |
Website | https://www.neuropace.com |
Stock Details
Ticker Symbol | NPCE |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001528287 |
CUSIP Number | 641288105 |
ISIN Number | US6412881053 |
Employer ID | 22-3550230 |
SIC Code | 3841 |
Key Executives
Name | Position |
---|---|
Joel D. Becker | Chief Executive Officer, President & Director |
Rebecca L. Kuhn | Chief Financial Officer and Vice President of Finance & Administration |
Amy Treadwell | Vice President of Human Resources |
Dr. Martha J. Morrell M.D. | Chief Medical Officer |
Dylan St. John | Chief of Operations & Development |
Katie Keller | Vice President of Marketing |
Kelley Nicholas | Vice President of Sales |
Leah Akin | General Counsel & Corporate Secretary |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 24, 2025 | 4 | Filing |
Mar 20, 2025 | 4 | Filing |
Mar 20, 2025 | 4 | Filing |
Mar 05, 2025 | 4 | Filing |
Mar 05, 2025 | 4 | Filing |
Mar 04, 2025 | S-8 | Filing |
Mar 04, 2025 | 10-K | Annual Report |
Mar 04, 2025 | 8-K | Current Report |
Mar 03, 2025 | 4 | Filing |
Mar 03, 2025 | 4 | Filing |